New malaria vaccine trial aims to stop recurrent fever
NCT ID NCT07373301
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental vaccine called PvCS/Montanide ISA-51 to see if it can protect against P. vivax malaria, a major cause of recurrent fever and anemia. 72 healthy adults in Colombia will receive either the vaccine or a placebo, then be exposed to infected mosquitoes under medical supervision. Researchers will monitor who gets infected and track side effects to determine if the vaccine is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PvCS/Montanide ISA-51 vaccine (a synthetic peptide from the malaria parasite combined with an immune-boosting adjuvant)
What this could lead to
If successful, this could lead to the first licensed vaccine against P. vivax malaria, preventing recurrent fever and illness in tropical regions.
What could go wrong
This is a Phase 2 trial with only 72 participants, so results may not apply to larger populations. The vaccine may not provide strong or lasting protection, and side effects like injection-site reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA PREVENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Malaria Vaccine and Drug Development Center (MVDC)
Cali, Valle del Cauca Department, 61000, Colombia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••